AGA临床实践指南:储袋炎及炎性储袋疾病的管理
美国胃肠病学会(AGA)基于GRADE框架制定指南,针对溃疡性结肠炎行回肠储袋肛管吻合术后的储袋炎、储袋克罗恩样病及袖口炎给出9条条件性推荐,并指出知识空白与未来研究方向。
要点
- 间歇性储袋炎症状者,AGA建议使用抗生素治疗。
- 抗生素应答的复发性储袋炎,AGA建议使用益生菌预防复发。
- 慢性抗生素依赖型储袋炎建议长期抗生素预防;不耐受或担忧长期风险者建议先进免疫抑制治疗。
核心结论
- 该指南为储袋炎及其他储袋炎性病变的管理提供了以患者为中心的综合方法。
研究设计与样本
- 美国胃肠病学会(AGA)组织多学科专家组及指南方法学家,采用推荐分级的评估、制定与评价(GRADE)框架制定本指南。
主要发现
- AGA指南专家组共提出9条条件性推荐。
- 指南还提出了储袋炎和储袋克罗恩样病优化管理的关键实施考虑,并识别了若干知识空白和未来研究方向。
关键数值与推荐
- 溃疡性结肠炎行回肠储袋肛管吻合术后出现间歇性储袋炎症状者,AGA建议使用抗生素治疗储袋炎。
- 抗生素应答的复发性储袋炎患者,AGA建议使用益生菌预防储袋炎复发。
- 慢性抗生素依赖型储袋炎患者,AGA建议使用长期抗生素治疗以预防储袋炎复发;但对抗生素不耐受或担忧长期抗生素治疗风险者,AGA建议使用获批用于治疗炎症性肠病的先进免疫抑制治疗(如生物制剂和/或口服小分子药物)。
- 慢性抗生素难治型储袋炎患者,AGA建议使用先进免疫抑制治疗;此类患者也可考虑糖皮质激素。
- 因储袋克罗恩样病出现症状者,AGA建议使用糖皮质激素和先进免疫抑制治疗;因袖口炎出现症状者,AGA建议使用获批用于治疗溃疡性结肠炎的疗法,从局部美沙拉秦或局部糖皮质激素开始。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Pouchitis is the most common complication after restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. This American Gastroenterological Association (AGA) guideline is intended to support practitioners in the management of pouchitis and inflammatory pouch disorders. METHODS: A multidisciplinary panel of content experts and guideline methodologists used the Grading of Recommendations Assessment, Development and Evaluation framework to prioritize clinical questions, identify patient-centered outcomes, conduct an evidence synthesis, and develop recommendations for the prevention and treatment of pouchitis, Crohn's-like disease of the pouch, and cuffitis. RESULTS: The AGA guideline panel made 9 conditional recommendations. In patients with ulcerative colitis who have undergone ileal pouch-anal anastomosis and experience intermittent symptoms of pouchitis, the AGA suggests using antibiotics for the treatment of pouchitis. In patients who experience recurrent episodes of pouchitis that respond to antibiotics, the AGA suggests using probiotics for the prevention of recurrent pouchitis. In patients who experience recurrent pouchitis that responds to antibiotics but relapses shortly after stopping antibiotics (also known as "chronic antibiotic-dependent pouchitis"), the AGA suggests using chronic antibiotic therapy to prevent recurrent pouchitis; however, in patients who are intolerant to antibiotics or who are concerned about the risks of long-term antibiotic therapy, the AGA suggests using advanced immunosuppressive therapies (eg, biologics and/or oral small molecule drugs) approved for treatment of inflammatory bowel disease. In patients who experience recurrent pouchitis with inadequate response to antibiotics (also known as "chronic antibiotic-refractory pouchitis"), the AGA suggests using advanced immunosuppressive therapies; corticosteroids can also be considered in these patients. In patients who develop symptoms due to Crohn's-like disease of the pouch, the AGA suggests using corticosteroids and advanced immunosuppressive therapies. In patients who experience symptoms due to cuffitis, the AGA suggests using therapies that have been approved for the treatment of ulcerative colitis, starting with topical mesalamine or topical corticosteroids. The panel also proposed key implementation considerations for optimal management of pouchitis and Crohn's-like disease of the pouch and identified several knowledge gaps and areas for future research. CONCLUSIONS: This guideline provides a comprehensive, patient-centered approach to the management of patients with pouchitis and other inflammatory conditions of the pouch.
引用
- Barnes EL, Agrawal M, Syal G, et al. AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders. Gastroenterology. 2024. PMID: 38128971. doi:10.1053/j.gastro.2023.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。